The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Pacira BioSciences Inc shares valued at $34,324 were sold by RIKER LAUREN on Jan 05 ’26. At $24.24 per share, RIKER LAUREN sold 1,416 shares. The insider’s holdings dropped to 59,064 shares worth approximately $1.31 million following the completion of this transaction.
Also, RIKER LAUREN purchased 1,416 shares, netting a total of over 34,324 in proceeds.
Before that, Cross Shawn had sold 15,896 shares from its account. In a trade valued at $397,877, the Chief Financial Officer traded Pacira BioSciences Inc shares for $25.03 each. Upon closing the transaction, the insider’s holdings decreased to 15,896 shares, worth approximately $1.25 million.
As published in their initiating research note from Barclays on December 09, 2025, Pacira BioSciences Inc [PCRX] has been an Equal weight and the price target has been revised to $27. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in mid November. As of July 25, 2025, Truist has increased its “Hold” rating to a “Buy” for PCRX. Earlier on January 30, 2025, Truist upgraded its rating. Their new recommendation was “a Hold” for PCRX stock which previously was a “a Sell”.
Analyzing PCRX Stock Performance
On last trading session, Pacira BioSciences Inc [NASDAQ: PCRX] rose 2.96% to $22.24. The stock’s lowest price that day was $21.35, but it reached a high of $22.51 in the same session. During the last five days, there has been a drop of approximately -14.46%. Over the course of the year, Pacira BioSciences Inc shares have jumped approximately 5.25%.
Is Pacira BioSciences Inc subject to short interest?
Stocks of Pacira BioSciences Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.14 million shares to 7.36 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 7.22 million shares. A jump of 1.86% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.81 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.81.
Which companies own the most shares of Pacira BioSciences Inc (PCRX)?
In terms of Pacira BioSciences Inc share price expectations, FactSet research, analysts set an average price target of 27 in the next 12 months, up nearly 25.0% from the previous closing price of $21.6. Analysts anticipate Pacira BioSciences Inc stock to reach 27 by 2026, with the lowest price target being 27. In spite of this, 6 analysts ranked Pacira BioSciences Inc stock as Buy at the end of 2026. On August 13, 2024, Truist assigned a price target of “a Sell” to the stock and downgraded coverage with a $8.
